Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects? [electronic resource]
Producer: 20200624Description: 915-918 p. digitalISSN:- 1096-9071
- Aged, 80 and over
- Anemia -- complications
- Antiviral Agents -- therapeutic use
- Betacoronavirus -- drug effects
- Biomarkers -- blood
- COVID-19
- COVID-19 Testing
- Clinical Laboratory Techniques -- methods
- Convalescence
- Coronavirus Infections -- complications
- Critical Illness
- Erythropoietin -- therapeutic use
- Fever -- complications
- Humans
- Iran
- Male
- Pandemics
- Pneumonia, Viral -- complications
- RNA, Viral -- blood
- Reverse Transcriptase Polymerase Chain Reaction
- SARS-CoV-2
- Tachycardia -- complications
- Tachypnea -- complications
- Tomography, X-Ray Computed
- Treatment Outcome
No physical items for this record
Publication Type: Case Reports; Journal Article
There are no comments on this title.
Log in to your account to post a comment.